It’s time to directly
Target Muscle in SMA
ISEMBYLD™ is a prescription medicine used to treat spinal muscular atrophy (SMA) in adults and children 2 years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment.
Mindy
Treated with ISEMBYLD.
Paid spokesperson.
ISEMBYLD is the first and only FDA-approved treatment for SMA to directly target the muscle
What it does
It blocks a process that limits muscle growth, enabling your muscles to receive the message to grow.
Who it’s for
It’s for adults and children aged 2 years and older who are on SMN2-targeted treatments (Spinraza® [nusinersen] or Evrysdi® [risdiplam]).*
How it helps
It’s designed to improve motor function beyond SMN2-targeted treatment alone.
See the results
FDA=US Food and Drug Administration.
ISEMBYLD works with—not in place of—your SMN2-targeted treatment
SMN2‑targeted treatments are important because they directly target the motor neuron. ISEMBYLD directly targets the muscle, the other key part of the motor unit that drives motor function. Used together, this treatment approach helps evolve care for children and adults living with SMA.
ISEMBYLD
directly targets the muscle
It blocks myostatin, a protein that limits muscle growth—because muscle is critical to motor function.
SMN2-targeted treatments that directly target the motor neuron
They increase the amount of SMN protein to help motor neurons keep transmitting signals to move the muscles.
Advancements over the last decade have redefined the SMA treatment landscape. ISEMBYLD offers an innovative way to help build on that progress.
Directly targeting muscle in SMA is now possible.
Talk to your doctor today about ISEMBYLD.
“We have seen gains in things that are visible and not visible for him, and that’s been so incredible for us to see.”
‐ Ashley (Christopher’s mom)
Paid spokesperson.
Individual patient experience.
Results may vary.